Invest more in RnD, develop new markets to boost pharma exports: Prabhu to industry

Published On 2018-05-12 05:26 GMT   |   Update On 2018-05-12 05:26 GMT

New Delhi: Commerce and Industry Minister Suresh Prabhu today asked pharma firms to increase R&D investments and develop new markets to boost the exports.


He also called for finding ways to make healthcare more affordable to people by reducing costs.






"Make more investments in R&D activities so that the pipeline (for new medicines) do not get dry," he said, adding that research and development investments will domestic growth.


The government is taking steps to boost pharma exports such as seeking greater market access for India's products in countries like China.


"China has agreed to organise a round table meet with our regulators. This will help in addressing market penetration issues," he added.


In 2017-18, the country's pharma exports stood at about USD 17 billion.


He further said that increasing cost of healthcare is a global concern and the Indian industry needs to work on this area to overcome the challenge.


Commerce Secretary Rita Teaotia said the market size of the global pharma industry is over USD 1 trillion and it holds huge potential for countries like India.


"We have to make healthcare affordable," she said.


S Eswara Reddy, Drugs Controller General of India (DCGI), said that they are taking steps to promote ease of doing business in the sector.


He informed that it has been decided to increase the validity of WHO (World Health Organisation) GMP (Good Manufacturing Practice) certification to three years for two years currently.


The move would help reduce delay in the registration process and promote exports, he said, adding that applications are now processed and approved online.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News